The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer.
Abstract
PURPOSE: This phase II study was conducted to evaluate the efficacy and toxicity of docetaxel in the treatment of patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Docetaxel was administered to 29 patients with unresectable stage III and IV NSCLC at a dose of 100 mg/m2 intravenously (IV) over 1 hour every 21 days. No premedication was given to the first 16 patients. Premedication with diphenhydramine was instituted for the remainder. No patient had previously received chemotherapy. Seven patients had undergone prior radiation therapy. RESULTS: All patients were assessable for response and toxicity. Eleven of 29 patients (38%) had a major objective response (95% confidence interval, 21% to 58%). The median duration of response was 5.3 months. Febrile neutropenia occurred in 41% of patients and in 11% of 134 courses of docetaxel. Nonhematologic toxicities included infusion-related hypersensitivity reactions, fluid retention, rash, alopecia, and sensory neuropathy. Premedication with diphenhydramine did not decrease the incidence of infusion-related hypersensitivity reactions. CONCLUSION: At this dose and schedule, docetaxel demonstrates significant antitumor activity in patients with advanced NSCLC. Further investigations of this agent in NSCLC are indicated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Cited by
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
Groopman, J. E., & Itri, L. M. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.19.1616 · Cited by 929
THE DEVELOPMENT AND CLINICAL UTILITY OF THE TAXANE CLASS OF ANTIMICROTUBULE CHEMOTHERAPY AGENTS
Rowinsky, M. (1997) · Annual Review of Medicine · doi:10.1146/annurev.med.48.1.353 · Cited by 721
Shaker, M. S., Wallace, D. V., Golden, D. B. K., Oppenheimer, J., Bernstein, J. A., Campbell, R. L., Dinakar, C., Ellis, A., Greenhawt, M., Khan, D. A., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.01.017 · Cited by 715
Gemcitabine and Docetaxel in Patients With Unresectable Leiomyosarcoma: Results of a Phase II Trial
Hensley, M. L., Maki, R., Venkatraman, E., Geller, G., Lovegren, M., Aghajanian, C., Sabbatini, P., Tong, W., Barakat, R., & Spriggs, D. R. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.050 · Cited by 683
Metadata
- Authors
- Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., & Heelan, R. T.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-06
- Volume
- 12
- Issue
- 6
- Pages
- 1232-1237
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1826360242
- Cited by
- 216
- References
- 1
- FWCI
- 13.36
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. https://app.cochat.ai/papers/10.1200/jco.1994.12.6.1232
- The paper
- Francis, P. A., Rigas, J. R., Kris, M. G., Pisters, K. M., Orazem, J. P., Woolley, K. J., & Heelan, R. T. (1994). Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.6.1232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.